Trial NCT04450004
Publication Ward B, 2020
Primary outcome on the report: Adverse events. The primary immunological outcomes were neutralizing antibody (NAb) responses measured using a VSV pseudovirion assay (Nexelis Inc, Laval, QC) and IFN-y and IL-4 cellular responses measured by ELISpot at D0, 21 and 42.